Robert Emanuele
Director/Board Member bei ARTELO BIOSCIENCES, INC.
Vermögen: 1 234 $ am 31.03.2024
Profil
Robert Martin Emanuele is the founder of Visgenx, Inc. He currently holds the position of President & Chief Executive Officer at Liferaft Biosciences, Inc. and is an Independent Director at Artelo Biosciences, Inc. He previously served as President & Chief Executive Officer at Synthrx, Inc. from 2008 to 2010.
Additionally, he held the position of Vice President-Research & Business Development at LadRx Corp.
from 1988 to 2002.
Dr. Emanuele also worked as Vice President-Pharmaceutical Strategy at DaVita, Inc. in 2010 and as Senior Vice President-Development at Mast Therapeutics, Inc. from 2011 to 2016.
He was Senior Vice President-Business Development at Kémia, Inc. from 2006 to 2008 and served as VP-Corporate Development & Portfolio Management at Avanir Pharmaceuticals, Inc. from 2002 to 2006.
Furthermore, he has experience as Chief Business Officer at Virobay, Inc., Clinical Research Scientist at Dupont Critical Care, Inc., and Senior Vice President-Development at Savara, Inc. Dr. Emanuele obtained his undergraduate degree from Colorado State University, an MBA from The University of Colorado, and a doctorate from Stritch School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ARTELO BIOSCIENCES INC
0,03% | 22.03.2024 | 834 ( 0,03% ) | 1 234 $ | 31.03.2024 |
Aktive Positionen von Robert Emanuele
| Unternehmen | Position | Beginn |
|---|---|---|
| ARTELO BIOSCIENCES, INC. | Director/Board Member | 20.09.2017 |
| Liferaft Biosciences, Inc. , | Chief Executive Officer | - |
Visgenx, Inc.
 Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Founder | - |
Ehemalige bekannte Positionen von Robert Emanuele
| Unternehmen | Position | Ende |
|---|---|---|
| SAVARA INC. | Corporate Officer/Principal | 28.10.2016 |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.10.2016 |
| DAVITA INC. | Corporate Officer/Principal | 01.04.2011 |
Synthrx, Inc.
 Synthrx, Inc. Miscellaneous Commercial ServicesCommercial Services Synthrx, Inc. develops a purified form of a rheologic and antithrombotic agent solution. The company is headquartered in Bellaire, TX. | Chief Executive Officer | 01.04.2010 |
Kémia, Inc.
 Kémia, Inc. Pharmaceuticals: MajorHealth Technology Kémia, Inc. discovered and developed novel small molecule therapeutics for inflammation, cancer, HIV, diabetes and bone diseases. The firm specialized in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development. The company was founded in 2002 and was headquartered in San Diego, CA. | Corporate Officer/Principal | 01.05.2008 |
Ausbildung von Robert Emanuele
| Colorado State University | Undergraduate Degree |
| The University of Colorado | Masters Business Admin |
| Stritch School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| LADRX CORPORATION | Health Technology |
| DAVITA INC. | Health Services |
| ARTELO BIOSCIENCES, INC. | Health Technology |
| SAVARA INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
EIDP, Inc.
 EIDP, Inc. Chemicals: AgriculturalProcess Industries EIDP, Inc. engages in the provision of science-based products and services. It operates through the Seed and Crop Protection segments. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms around the world. The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The company was founded by Eleuthere Irenee du Pont in 1802 and is headquartered in Indianapolis, IN. | Process Industries |
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
Kémia, Inc.
Kémia, Inc. Pharmaceuticals: MajorHealth Technology Kémia, Inc. discovered and developed novel small molecule therapeutics for inflammation, cancer, HIV, diabetes and bone diseases. The firm specialized in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development. The company was founded in 2002 and was headquartered in San Diego, CA. | Health Technology |
Virobay, Inc.
 Virobay, Inc. Pharmaceuticals: MajorHealth Technology Virobay, Inc. develops protease inhibitors for the treatment of neuropathic pain, cancer, autoimmune and liver diseases. It utilize cysteine cathepsin platform for the development and commercialization of novel drugs. The firm's research & development activities focuses on neuropathic pain, autoimmune diseases and liver fibrosis. The company was founded by Robert F. G. Booth on May 18, 2006 and is headquartered in Menlo Park, CA. | Health Technology |
| Dupont Critical Care, Inc. | |
Synthrx, Inc.
Synthrx, Inc. Miscellaneous Commercial ServicesCommercial Services Synthrx, Inc. develops a purified form of a rheologic and antithrombotic agent solution. The company is headquartered in Bellaire, TX. | Commercial Services |
| Liferaft Biosciences, Inc. , | Miscellaneous |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Health Technology |
